Quarterly report pursuant to Section 13 or 15(d)

Calculated Based on Number of Shares of Combined Company Pre-Merger (Detail)

v3.8.0.1
Calculated Based on Number of Shares of Combined Company Pre-Merger (Detail)
 3 Months Ended
Mar. 31, 2018
USD ($)
$ / shares
shares
Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders | shares 6,109,205 [1]
Multiplied by the price per share of ApolloMed’s common stock | $ / shares $ 10 [2]
Equity consideration | $ $ 61,092,050 [3]
[1] Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.
[2] Represents the closing price of ApolloMed’s common stock on December 8, 2017.
[3] Equity consideration Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of 6,109,205 shares of ApolloMed common stock.